Navigation Links
Regenicin to Present Live at RetailInvestorConferences.com on November 4th
Date:10/29/2010

NEW YORK, Oct. 29 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDST) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that the Company's Chief Executive Officer, Randall McCoy and Chief Financial Officer, John Weber will present at RetailInvestorConferences.com.DATE:

November 4, 2010TIME:

7:00 PM ESTLINK:

www.retailinvestorconferences.comThis will be a live, interactive online event where investors are invited to ask Regenicin questions in real-time both in the presentation hall as well as at the company's "virtual trade booth." If attendees are not able to join the event live an archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About RegenicinRegenicin, Inc., is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin's therapeutic candidate, PermaDerm™, is an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns.  The company is publicly traded with headquarters in New York City.

About RetailInvestorConferences.comRetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>

SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
2. Regenicin to Form Scientific Advisory Board
3. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
4. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
5. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
6. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
7. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
8. Beckman Coulter to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
11. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):